HelpAcademyLoginJoin us as a Member

Mitapivat matched

Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yetListed from FDA or ClinicalTrials.gov records; an editor has not checked it yet.

AGIOS PHARMACEUTICALS, INC. AGIO · Sickle Cell Disease; Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia

Sign in to save Mitapivat matched to a watchlist Sign in to set an alert for Mitapivat matched

Key figures

  • Next catalyst

    None scheduled

    Only dates with a source are listed

  • Phase

    Phase 3

    Not recorded

  • Linked trials

    2

    From ClinicalTrials.gov

  • Latest FDA action

    None on record

    From Drugs@FDA

Recalls, shortages, patents and EU status at a glance

Key information

Sponsor
AGIOS PHARMACEUTICALS, INC. AGIO Source: Company record for AGIOS PHARMACEUTICALS, INC. (opens in a new tab)
Indications
Sickle Cell Disease; Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia Source: Conditions from ClinicalTrials.gov (opens in a new tab)
Designations
None recorded
Next catalyst
None scheduled

Development timeline

  1. Preclinical Completed
  2. Phase 1 Completed
  3. Phase 2 Completed
  4. Phase 3 Current stageFirst trial start 21 Jul 20262 linked trials
  5. Filed Not yet
  6. Approved Not yet

Overview

Mechanism
Not recorded
Route
Not recorded
Modality
Not recorded
Specialties
Not recorded

Overview text is written by HealthTrade editors.

Key dates

No catalysts yet. Editors add each date together with its source.

FDA designations

No FDA designations are on record for Mitapivat matched. Editors add each one with its source.

Filed application

No filed application is on record for Mitapivat matched. Approvals are listed under FDA actions.

FDA advisory committees

No FDA advisory committee meetings are on record for Mitapivat matched.

Clinical trials

Trials linked to Mitapivat matched
TrialTitlePhaseStatusEnrollmentPrimary completionResults posted
NCT07506863ClinicalTrials.gov record for NCT07506863 (opens in a new tab)ENERGIZEKids-TA Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Phase 3Recruiting54 (estimated)Jun 2029 (estimated) No
NCT07656415ClinicalTrials.gov record for NCT07656415 (opens in a new tab)A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)Phase 3Recruiting159 (estimated)Aug 2029 (estimated) No

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Posted results are shown as ClinicalTrials.gov prints them; results from company and journal sources are entered by editors and listed separately. Full result tables are on ClinicalTrials.gov.

Trial quality

About CT-VCA

Loading trial quality…

FDA actions

No FDA approvals on record for this drug.

FDA recalls load here.

FDA drug shortages load here.

Orange Book patents load here.

FAERS adverse event counts load here.

Papers and preprints load here.

Community discussion loads here.

EU status (EMA)

EMA's medicines data lists no human medicine with the same active substance as Mitapivat matched.

Source: European Medicines Agency (EMA), medicines data download.

Related news

No recent headlines mention this drug.

Sources

Record updated .

Dates come from company and FDA disclosures and can change. Nothing on this page is investment advice.